Neoleukin Therapeutics Inc (NLTX)
1.00
-0.06 (-5.66%)
USD |
NASDAQ |
Aug 09, 12:35
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 42.50M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -84.92% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.3267 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 94.63% |
News
Headline
Wire
Time (ET)
Globe Newswire
08/03 08:00
Globe Newswire
07/27 08:00
MT Newswires
07/06 10:38
Yahoo
07/04 06:42
MT Newswires
05/31 05:10
MT Newswires
05/16 10:48
Yahoo
05/16 08:00
MT Newswires
05/10 14:21
Globe Newswire
05/09 16:05
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 08/09/2022 | -- | Results | Q2 2022 | -- | -0.30 | -- | |
| 08/09/2022 | 16:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/09/2022 | -- | Results | Q1 2022 | -0.28 | -0.30 | 6.04% | |
| 03/01/2022 | -- | Results | Q4 2021 | -0.28 | -0.29 | 3.45% | |
| 03/01/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
| 11/04/2021 | -- | Results | Q3 2021 | -0.28 | -0.28 | -1.82% | |
| 08/05/2021 | -- | Results | Q2 2021 | -0.27 | -0.27 | 1.22% | |
| 05/12/2021 | -- | Results | Q1 2021 | -0.27 | -0.23 | -17.39% |
*Estimated Date/Time
Earnings
Profile
Edit
| Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. |
| URL | https://www.neoleukin.com |
| Investor Relations URL | http://investor.aqxpharma.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 09, 2022 |
| Last Earnings Release | Aug. 09, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of August 08, 2022.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 61.12M |
| Net Income (TTM) | -61.09M |
| Total Assets (Quarterly) | 149.13M |
| Total Liabilities (Quarterly) | 19.03M |
| Shareholders Equity (Quarterly) | 130.09M |
| Cash from Operations (TTM) | -48.29M |
| Cash from Investing (TTM) | -2.626M |
| Cash from Financing (TTM) | 0.583M |
Ratings
Profile
Edit
| Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. |
| URL | https://www.neoleukin.com |
| Investor Relations URL | http://investor.aqxpharma.com/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 09, 2022 |
| Last Earnings Release | Aug. 09, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| NLTX Tweets |